{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:29:12Z","timestamp":1761625752716,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.dld.2022.06.029","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T07:25:19Z","timestamp":1658474719000},"page":"230-234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Laura","family":"Melotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas Konstantine","family":"Dussias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Salice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monia","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Scaioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Belluzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.dld.2022.06.029_bib0001","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dld.2022.06.029_bib0002","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.12749","article-title":"Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease","volume":"39","author":"Stidham","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dld.2022.06.029_bib0003","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.dld.2022.06.029_bib0004","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"Allez","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.dld.2022.06.029_bib0005","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.dld.2022.06.029_bib0006","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.dld.2022.06.029_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dld.2022.06.029_bib0008","article-title":"Anti-IL-12\/23p40 antibodies for induction of remission in Crohn's disease","volume":"11","author":"Macdonald","year":"2016","journal-title":"Cochrane database Syst Rev"},{"issue":"20","key":"10.1016\/j.dld.2022.06.029_bib0009","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.dld.2022.06.029_bib0010","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.dld.2020.07.031","article-title":"The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab","volume":"52","author":"Kassouri","year":"2020","journal-title":"Dig Liver Dis"},{"issue":"8167","key":"10.1016\/j.dld.2022.06.029_bib0011","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn's-disease activity","volume":"315","author":"Harvey","year":"1980","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dld.2022.06.029_bib0012","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/ecco-jcc\/jjy097","article-title":"Defining endoscopic remission in ileocolonic Crohn's disease: let's start from scratch","volume":"12","author":"Bossuyt","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"13","key":"10.1016\/j.dld.2022.06.029_bib0013","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/jcm10132914","article-title":"Effectiveness of third-class biologic treatment in Crohn's disease: a multi-center retrospective cohort study","volume":"10","author":"Albshesh","year":"2021","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.dld.2022.06.029_bib0014","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.dld.2021.07.008","article-title":"Clinical efficacy, drug sustainability and serum drug levels in Crohn's disease patients treated with ustekinumab - a prospective, multicenter cohort from Hungary","volume":"54","author":"Gonczi","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.dld.2022.06.029_bib0015","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/apt.15958","article-title":"Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry","volume":"52","author":"Iborra","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dld.2022.06.029_bib0016","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/flgastro-2019-101237","article-title":"Early real-world effectiveness of ustekinumab for Crohn's disease","volume":"11","author":"Harris","year":"2019","journal-title":"Frontline Gastroenterol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822005825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865822005825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:20:59Z","timestamp":1761625259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865822005825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1590865822005825"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2022.06.029","relation":{},"ISSN":["1590-8658"],"issn-type":[{"type":"print","value":"1590-8658"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2022.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}